Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 1, 2019Oncology

Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma

View Full Paper
Ask AI
Bookmark
Share

Authors

AHAtsushi HiraokaEhime Prefectural Central HospitalTKTakashi KumadaHiroshima UniversityMAMasanori AtsukawaNippon Medical School

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Hiraoka et al. (2019) studied this question.

synapsesocial.com/papers/6a7c1856073f483584dfb745https://doi.org/10.1159/000501281
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions: Multicenter analysis2018 · 132 citations
  2. 2Imaging Study of Early Hepatocellular Carcinoma: Usefulness of Gadoxetic Acid–enhanced MR Imaging2011 · 355 citations
  3. 3Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics2012 · 19,341 citations
  4. 4Transection of the oesophagus for bleeding oesophageal varices1973 · 8,035 citations
  5. 5Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function2017 · 343 citations